SCHEMBL5115045

SCHEMBL5115045

Nc1ncc(-c2ccc3nc(NCc4ccc(S(N)(=O)=O)cc4)nc(NCC(F)(F)F)c3n2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
CA1 P00915 13/20 0.42
CA2 P00918 13/20 0.42
CA9 Q16790 13/20 0.42
PTGS2 P35354 1/20 0.41
CA12 O43570 2/20 0.39
CA14 Q9ULX7 2/20 0.39
STK17B O94768 1/20 0.38
CSF1R P07333 1/20 0.38
IKBKE Q14164 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
LRRK2 Q5S007 1/20 0.38
ULK3 Q6PHR2 1/20 0.38
NUAK2 Q9H093 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
TBK1 Q9UHD2 1/20 0.38
ILK Q13418 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5113041 0.88 KDM4E (0.44) KDM4ENPC1MAPTCA1CA2
SCHEMBL5122252 0.86 KDM4E (0.44) KDM4ENPC1MAPTCA1CA2
SCHEMBL5110862 0.85 CA1 (0.47) KDM4ENPC1MAPTCA1CA2
SCHEMBL5121965 0.85 PTGS2 (0.48) KDM4ENPC1MAPTCA1CA2
SCHEMBL5115282 0.84 AXL (0.43) KDM4ENPC1MAPTCA1CA2
SCHEMBL5112341 0.83 PTGS2 (0.48) KDM4ENPC1MAPTCA1CA2
SCHEMBL5121981 0.83 PTGS2 (0.43) KDM4ENPC1MAPTCA1CA2
SCHEMBL5123142 0.82 PTGS2 (0.44) KDM4ENPC1MAPTCA1CA2
SCHEMBL5115285 0.82 PTGS2 (0.48) KDM4ENPC1MAPTCA1CA2
SCHEMBL5121534 0.82 PTGS2 (0.48) KDM4ENPC1MAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PNP KDM4E 3976/4885NPC1 2244/4885MAPT 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.